Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Doctors who administer prescription drugs in their offices to Medicare beneficiaries would have the option of getting lower-priced drugs from private vendors, under a proposed program being weighed by a federal advisory panel.
The changes discussed are aimed at reducing the 9 percent annual growth for Part B drugs that cost $26 billion in 2015.
Doctors could still buy Part B drugs directly from drug manufacturers and distributors and bill Medicare, but their reimbursements would be lower than they get currently to encourage enrollment in the market-based vendor program, staff for the Medicare Payment Advisory Commission said Jan. 13.
Medicare pays doctors for outpatient drug treatments, such as chemotherapy, based on manufacturers’ average sales price plus an additional 6 percent, known as ASP + 6 percent.
Medicare would encourage clinicians to join the vendor program, to be called the Drug Value Program, by gradually reducing the 6 percent add-on and making other changes to the current reimbursement system.
The changes wouldn’t happen overnight. The vendor program would be phased in with a subset of drugs and could take until 2022 to implement, staff said.
In the meantime, the “improved ASP system” for those who continue to buy and bill would be restructured in the next few years.
The commissioners will debate draft recommendations in March and are expected to vote on them in April.
In addition to reducing the ASP add-on, the changes would:
The new market-based program would allow vendors to negotiate prices with manufacturers and permit doctors and other providers who enroll to share in the savings. Beneficiaries would also save through lower cost sharing.
The model would resemble a group purchasing organization with multiple vendors that could use formularies and other management tools, such as step therapy and prior authorization, to keep prices down.
MedPAC Commissioner Brian DeBusk applauded the “multi-faceted” approach of the proposed program, which was developed by MedPAC staff. DeBusk is chief executive officer of DeRoyal Industries in Powell, Tenn.
Commissioner Rita Redberg, professor of clinical medicine at the University of California at San Francisco Medical Center, said the proposed provisions on consolidated billing would address concerns about biosimilars that are priced higher than brand name drugs.
Most of the other commissioners appeared interested in pursuing changes, although some had concerns.
For example, “behavioral economics” might lead some providers to increase the number of drugs they purchase to compensate for the lower add-on, Commissioner David Nerenz, director of the Detroit-based Center for Health Policy and Health Services Research at the Henry Ford Health System, said.
The new value program is a plus in that it would allow another entity to set different payment rates rather than just the ASP plus 6 percent, Commissioner Kathy Buto, a former deputy executive secretary for health at the Department of Health and Human Services, said. However, she added that more information is needed to see if the program will actually lower prices.
To contact the reporter on this story: Mindy Yochelson in Washington at MYochelson@bna.com
To contact the editor responsible for this story: Kendra Casey Plank at firstname.lastname@example.org
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)